bioscience accelerators

Colossal Biosciences, the US biotech company working to bring back extinct species such as the woolly mammoth, has announced a new AI platform to accelerate its de-extinction research. Entrepreneur Peter Diamandis has simultaneously launched a fund to back startups building on the platform, linking the effort to a wider wave of investment in applied AI for biotechnology.

Biotech company Colossal Biosciences says it is accelerating its project to resurrect the dodo, the flightless bird that went extinct in the late 17th century. The company is pushing forward a full de-extinction pipeline spanning genetic sequencing, editing and surrogate development. The dodo joins Colossal's better-known efforts on the woolly mammoth and the thylacine, keeping de-extinction science in the headlines.

Therna Biosciences has presented RNA-Logix, an AI-driven 'RNA biologist' platform designed to accelerate biological discovery and support the design of genomic medicines. The announcement was carried by Business Wire and picked up by life sciences news outlets. The company positions the technology as a way to automate RNA-focused research workflows for drug development, though no clinical or partnership details accompanied the reveal.

Colossal Biosciences, the US biotech company known for its efforts to bring back extinct species such as the woolly mammoth, has announced a new artificial intelligence platform. The company says the tool will help accelerate its de-extinction research by speeding up genomic analysis and related work. The announcement is drawing attention in science and technology circles, with observers weighing the promise of AI-driven biotech against ongoing debate about whether de-extinction is feasible or worth prioritising.